CN114989176A - 咪唑并哒嗪类衍生物及其应用 - Google Patents
咪唑并哒嗪类衍生物及其应用 Download PDFInfo
- Publication number
- CN114989176A CN114989176A CN202210804522.1A CN202210804522A CN114989176A CN 114989176 A CN114989176 A CN 114989176A CN 202210804522 A CN202210804522 A CN 202210804522A CN 114989176 A CN114989176 A CN 114989176A
- Authority
- CN
- China
- Prior art keywords
- group
- hydrogen
- substituted
- unsubstituted
- cyano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000005233 imidazopyridazines Chemical class 0.000 title claims abstract description 27
- 150000001875 compounds Chemical class 0.000 claims abstract description 57
- 150000003839 salts Chemical class 0.000 claims abstract description 30
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 14
- 229940002612 prodrug Drugs 0.000 claims abstract description 11
- 239000000651 prodrug Substances 0.000 claims abstract description 11
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 claims abstract description 9
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims abstract description 9
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims abstract description 9
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 claims abstract description 9
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims abstract description 9
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims abstract description 9
- 201000010099 disease Diseases 0.000 claims abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- 230000001404 mediated effect Effects 0.000 claims abstract description 6
- 101000850794 Homo sapiens Tropomyosin alpha-3 chain Proteins 0.000 claims abstract description 5
- 201000001441 melanoma Diseases 0.000 claims abstract description 5
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 4
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims abstract description 4
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims abstract description 4
- 201000007452 breast secretory carcinoma Diseases 0.000 claims abstract description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 4
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims abstract description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims abstract description 4
- 201000002510 thyroid cancer Diseases 0.000 claims abstract description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims abstract description 4
- -1 carbamido Chemical group 0.000 claims description 68
- 239000001257 hydrogen Substances 0.000 claims description 48
- 229910052739 hydrogen Inorganic materials 0.000 claims description 48
- 150000002431 hydrogen Chemical class 0.000 claims description 41
- 125000000217 alkyl group Chemical group 0.000 claims description 26
- 125000005843 halogen group Chemical group 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 21
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 125000001188 haloalkyl group Chemical group 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 13
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 13
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 102000001253 Protein Kinase Human genes 0.000 claims description 11
- 108060006633 protein kinase Proteins 0.000 claims description 11
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 125000006001 difluoroethyl group Chemical group 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 5
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 5
- 125000002757 morpholinyl group Chemical group 0.000 claims description 5
- 125000003386 piperidinyl group Chemical group 0.000 claims description 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 4
- 101100498819 Caenorhabditis elegans ddr-1 gene Proteins 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 125000003368 amide group Chemical group 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 125000003700 epoxy group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- 102100033080 Tropomyosin alpha-3 chain Human genes 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 abstract description 18
- 230000002401 inhibitory effect Effects 0.000 abstract description 16
- 230000004663 cell proliferation Effects 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 11
- 108091000080 Phosphotransferase Proteins 0.000 abstract description 10
- 102000020233 phosphotransferase Human genes 0.000 abstract description 10
- 102100036725 Epithelial discoidin domain-containing receptor 1 Human genes 0.000 abstract description 3
- 101710131668 Epithelial discoidin domain-containing receptor 1 Proteins 0.000 abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 239000000243 solution Substances 0.000 description 20
- 125000004432 carbon atom Chemical group C* 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 102100029166 NT-3 growth factor receptor Human genes 0.000 description 6
- 101150117329 NTRK3 gene Proteins 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 6
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 238000006069 Suzuki reaction reaction Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 229940125904 compound 1 Drugs 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- IQHXABCGSFAKPN-UHFFFAOYSA-N pyrrolidine-3-carboxamide Chemical compound NC(=O)C1CCNC1 IQHXABCGSFAKPN-UHFFFAOYSA-N 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 238000010609 cell counting kit-8 assay Methods 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 4
- 229940043355 kinase inhibitor Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 102100035080 BDNF/NT-3 growth factors receptor Human genes 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 101000596896 Homo sapiens BDNF/NT-3 growth factors receptor Proteins 0.000 description 3
- FNXWRNPAFFRYAW-LLVKDONJSA-N N[C@H](CC1)CN1C(C=C1)=NN2C1=NC=C2C1=NC=CC=C1 Chemical compound N[C@H](CC1)CN1C(C=C1)=NN2C1=NC=C2C1=NC=CC=C1 FNXWRNPAFFRYAW-LLVKDONJSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000007098 aminolysis reaction Methods 0.000 description 3
- 239000012300 argon atmosphere Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000013058 crude material Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000003674 kinase activity assay Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102100039064 Interleukin-3 Human genes 0.000 description 2
- IKJRKNZBCCOIFV-OAHLLOKOSA-N O=C(N[C@H](CC1)CN1C(C=C1)=NN2C1=NC=C2C1=NC=CC=C1)NC(C=C1)=CC(C(F)(F)F)=C1Cl Chemical compound O=C(N[C@H](CC1)CN1C(C=C1)=NN2C1=NC=C2C1=NC=CC=C1)NC(C=C1)=CC(C(F)(F)F)=C1Cl IKJRKNZBCCOIFV-OAHLLOKOSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 150000007514 bases Chemical class 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 2
- 229940121657 clinical drug Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 101150100366 end gene Proteins 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229950000521 entrectinib Drugs 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 229940076264 interleukin-3 Drugs 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- RUZLIIJDZBWWSA-INIZCTEOSA-N methyl 2-[[(1s)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoate Chemical group COC(=O)C1=CC=CC=C1N[C@@H](C)C1=CC(C)=CN2C(=O)C=C(N3CCOCC3)N=C12 RUZLIIJDZBWWSA-INIZCTEOSA-N 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- HAYYBYPASCDWEQ-UHFFFAOYSA-N n-[5-[(3,5-difluorophenyl)methyl]-1h-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC(C1=C2)=NNC1=CC=C2CC1=CC(F)=CC(F)=C1 HAYYBYPASCDWEQ-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000003909 protein kinase inhibitor Substances 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000010517 secondary reaction Methods 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- NYNZQNWKBKUAII-KBXCAEBGSA-N (3s)-n-[5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide Chemical compound C1[C@@H](O)CCN1C(=O)NC1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 NYNZQNWKBKUAII-KBXCAEBGSA-N 0.000 description 1
- BOOVIFJKQGYEON-UHFFFAOYSA-N 1-(oxan-4-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(C2CCOCC2)N=C1 BOOVIFJKQGYEON-UHFFFAOYSA-N 0.000 description 1
- UCNGGGYMLHAMJG-UHFFFAOYSA-N 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound C1=NN(C)C=C1B1OC(C)(C)C(C)(C)O1 UCNGGGYMLHAMJG-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QEHDAUWYRNEWBF-UHFFFAOYSA-N 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]ethanol Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CCO)N=C1 QEHDAUWYRNEWBF-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- WWTGXYAJVXKEKL-UHFFFAOYSA-N 3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)aniline Chemical compound C1=NC(C)=CN1C1=CC(N)=CC(C(F)(F)F)=C1 WWTGXYAJVXKEKL-UHFFFAOYSA-N 0.000 description 1
- TVOJIBGZFYMWDT-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CNN=C1 TVOJIBGZFYMWDT-UHFFFAOYSA-N 0.000 description 1
- ZMWAZMYBMAAMAW-UHFFFAOYSA-N 4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)aniline Chemical compound C1CN(C)CCN1CC1=CC=C(N)C=C1C(F)(F)F ZMWAZMYBMAAMAW-UHFFFAOYSA-N 0.000 description 1
- IWHCPHZAMFSDFM-UHFFFAOYSA-N 6-chloro-3-iodoimidazo[1,2-b]pyridazine Chemical compound N1=C(Cl)C=CC2=NC=C(I)N21 IWHCPHZAMFSDFM-UHFFFAOYSA-N 0.000 description 1
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010065859 Congenital fibrosarcoma Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 description 1
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- ZXICYZVMTZFRGD-UHFFFAOYSA-N N-methyl-3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)aniline Chemical compound CN1CCN(CC1)C=1C=C(NC)C=C(C=1)C(F)(F)F ZXICYZVMTZFRGD-UHFFFAOYSA-N 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 208000037323 Rare tumor Diseases 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 108010030743 Tropomyosin Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 238000005915 ammonolysis reaction Methods 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- DBLXOVFQHHSKRC-UHFFFAOYSA-N ethanesulfonic acid;2-piperazin-1-ylethanol Chemical compound CCS(O)(=O)=O.OCCN1CCNCC1 DBLXOVFQHHSKRC-UHFFFAOYSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229950003970 larotrectinib Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- VVWWZOKQKXPVIV-RXMQYKEDSA-N methyl (3r)-pyrrolidine-3-carboxylate Chemical compound COC(=O)[C@@H]1CCNC1 VVWWZOKQKXPVIV-RXMQYKEDSA-N 0.000 description 1
- VVWWZOKQKXPVIV-YFKPBYRVSA-N methyl (3s)-pyrrolidine-3-carboxylate Chemical compound COC(=O)[C@H]1CCNC1 VVWWZOKQKXPVIV-YFKPBYRVSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
- RDNQDSKTTPSVKZ-UHFFFAOYSA-N phenyl n-[4-chloro-3-(trifluoromethyl)phenyl]carbamate Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(NC(=O)OC=2C=CC=CC=2)=C1 RDNQDSKTTPSVKZ-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000004942 pyridazin-6-yl group Chemical group N1=NC=CC=C1* 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- FIKPXCOQUIZNHB-WDEREUQCSA-N repotrectinib Chemical compound C[C@H]1CNC(=O)C2=C3N=C(N[C@H](C)C4=C(O1)C=CC(F)=C4)C=CN3N=C2 FIKPXCOQUIZNHB-WDEREUQCSA-N 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- OEBIHOVSAMBXIB-SJKOYZFVSA-N selitrectinib Chemical compound C[C@@H]1CCC2=NC=C(F)C=C2[C@H]2CCCN2C2=NC3=C(C=NN3C=C2)C(=O)N1 OEBIHOVSAMBXIB-SJKOYZFVSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- DQQJBEAXSOOCPG-UHFFFAOYSA-N tert-butyl n-pyrrolidin-3-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNC1 DQQJBEAXSOOCPG-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005888 tetrahydroindolyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005307 thiatriazolyl group Chemical group S1N=NN=C1* 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 108010064892 trkC Receptor Proteins 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于生物医药技术领域,具体涉及一种咪唑并哒嗪类衍生物及其应用。本发明提供的咪唑并哒嗪类衍生物具有如式(Ⅰ)所示的结构,该咪唑并哒嗪类衍生物或其立体异构体、氘代化合物或其药学上可接受的盐或前药,对TRK、FLT3、RET、VEGFR2、DDR1等激酶具有不同程度的抑制作用,尤其是对TRKs激酶有很强的抑制活性,并且对Ba/F3‑TRKs稳定株的野生型及耐药型细胞增殖有很强的抑制活性。可以用于制备预防或者治疗由TRK酪氨酸激酶介导的疾病的药物,比如非小细胞肺癌、乳腺癌、结肠癌、前列腺癌、甲状腺癌、恶性黑色素瘤、神经母细胞瘤和乳腺样分泌癌等。
Description
技术领域
本发明属于生物医药技术领域,具体涉及一种咪唑并哒嗪类衍生物及其应用。
背景技术
原肌球蛋白受体激酶(Tropomyosin receptor kinase,TRK)属于经典的细胞表面的跨膜型受体酪氨酸激酶,由TRKA、TRKB、TRKC三个亚型组成,分别由NTRK1、NTRK2及NTRK3基因编码。在正常的生理条件下,胞外不同的神经营养因子(Neurotrophin,NT)结合并激活TRK激酶,活化的TRK激酶可以激活其下游信号通路(主要为PI3K/AKT通路,Ras/Raf/MAPK通路以及PLCγ/PKC通路),从而调控细胞的增殖、分化、存活、迁移等一系列生物学功能。研究表明当编码NTRK的3′端基因与其伴侣蛋白的5′端基因发生基因融合时,表达出的NTRK融合蛋白呈配体非依赖的形式激活,促进肿瘤细胞的增殖和存活。尽管NTRK基因融合在一些常见的肿瘤类型(如肺癌、乳腺癌、结肠癌等)发生频率较低(<5%),但在一些罕见肿瘤中它的发生率高达90%以上,例如先天纤维肉瘤、分泌性乳腺癌、先天性中胚层肾病,小儿黑色素瘤等。因此,TRK激酶被认为是一个有吸引力癌症治疗的“泛癌”药物靶标。目前,FDA批准了两款“不限癌种”TRK激酶抑制剂——拉罗替尼(Larotrectinib)和恩曲替尼(Entrectinib)的上市。
拉罗替尼(larotrectinib)是由LOXO Oncology公司开发的选择性TRKA/B/C抑制剂。恩曲替尼(entrectinib)是一个多靶点的激酶抑制剂,同时具有ALK、ROS1和TRKs等激酶抑制活性。这两款药物最初在携带NTRK融合肿瘤的患者体内产生了强大的肿瘤增殖抑制效果,然而随着临床的使用,获得性的临床耐药突变随之而来。位于TRK激酶ATP结合口袋的氨基酸点突变是第一代TRK抑制剂拉罗替尼和恩曲替尼的主要耐药机制,主要分为溶剂前沿点突变,如TRKAG595R、TRKCG623R、TRKCG623E;门控位点突变,如TRKAF589L;xDFG突变如TRKAG667C、TRKAG667A等。随后开发的第二代TRK抑制剂LOXO-195和TPX-0005等正处于临床研究中,他们主要针对TRK溶剂前沿等突变耐药,如TRKAG595R、TRKCG623R、TRKCG623E,而对xDFG突变效果欠佳,目前还没有针对这些突变的抑制剂上市。
发明内容
有鉴于此,本发明的目的在于提供一种咪唑并哒嗪类衍生物,以作为蛋白激酶抑制剂,能够有效抑制TRK、RET、FLT3、VEGFR2、DDR1等蛋白激酶的活性并且能抑制多种肿瘤细胞的增殖、迁移和侵袭,尤其可以克服现有临床药物的耐药性。
本发明所提供的技术方案如下:
第一方面,本发明提供了一种具有如式(Ⅰ)所示结构的咪唑并哒嗪类衍生物或其立体异构体、氘代化合物或其药学上可接受的盐或前药:
其中,L选自酰胺基、脲基、砜基、亚硫酰基、磺酰胺基中的一种,
R1选自氢、卤基、氰基、羟基、烷基、烷氧基、卤代烷基中的一种,
R2和R3各自独立地选自氢、卤基、氰基、羟基、烷基、烷氧基、卤代烷基、烷基胺基、取代或未取代的杂环烷基、取代或未取代的杂芳基中的一种,
R4选自氢、R5取代或未取代的芳基、R5取代或未取代的杂芳基中的一种,R5选自氢、卤基、氨基、羟基、氰基、烷基、环烷基、烷氧基、环氧基、羟烷基、胺基中的至少一种。
在其中一些实施例中,R1选自氢、卤基、氰基、羟基、C1-C20烷基、C1-C20烷氧基、C1-C20卤代烷基中的一种;和/或
R2选自氢、卤基、氰基、羟基、C1-C20卤代烷基、取代或未取代的杂环烷基、取代或未取代的杂芳基中的一种,所述杂环烷基或所述杂芳基中的杂原子个数为1-3,所述杂环烷基具有5-10元环结构,所述杂环烷基中的杂原子为N、O或S,所述杂芳基具有5-6元环结构,所述杂芳基中的杂原子为N;和/或
R3选自氢、卤基、氰基、羟基、C1-C20烷基、C1-C20卤代烷基、C1-C20烷氧基、取代或未取代的杂环烷基、取代或未取代的杂芳基中的一种,所述杂环烷基或所述杂芳基中的杂原子个数为1-3,所述杂原子为N,所述杂环烷基或所述杂芳基具有5-10元环结构。
在其中一些实施例中,L选自酰胺或脲基;和/或
R1选自氢、卤基、氰基、羟基、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基中的一种;和/或
R2选自氢、卤基、氰基、羟基、C1-C4卤代烷基、取代或未取代的N-杂环烷基、取代或未取代的N-杂芳基、-(CH2)xR6中的至少一种,所述N-杂环烷基和所述N-杂芳基具有5-6元环结构,x为1-5的整数,R6为C1-C5烷基取代或未取代的吗啉基、吡咯烷基、哌啶基或哌嗪基;和/或
R3选自氢、卤基、氰基、羟基、烷基、卤代烷基、烷氧基、取代或未取代的N-杂环烷基、取代或未取代的N-杂芳基、-(CH2)xR6中的至少一种,所述N-杂环烷基和所述N-杂芳基具有5-6元环结构,x为1-5的整数,R6为C1-C5烷基取代或未取代的吗啉基、吡咯烷基、哌啶基或哌嗪基;和/或
R1选自氢、氟、氰基、羟基、甲基、乙基、异丙基、叔丁基、二氟甲基、二氟乙基、三氟甲基或三氟乙基;和/或
R1选自氢、氟、甲基、乙基、异丙基、叔丁基、二氟甲基、二氟乙基、三氟甲基或三氟乙基;和/或
在其中一些实施例中,所述咪唑并哒嗪类衍生物选自以下任一化合物:
经实验证实,以上提供的咪唑并哒嗪类衍生物或其立体异构体、氘代化合物或其药学上可接受的盐或前药,对TRK、FLT3、RET、VEGFR2、DDR1等激酶具有不同程度的抑制作用,尤其是对TRKs激酶有很强的抑制活性,并且对Ba/F3-TRKs稳定株的野生型及耐药型细胞增殖有很强的抑制活性。可以用于制备预防或者治疗由TRK酪氨酸激酶介导的疾病的药物,比如非小细胞肺癌、乳腺癌、结肠癌、前列腺癌、甲状腺癌、恶性黑色素瘤、神经母细胞瘤和乳腺样分泌癌等。
第二方面,本发明还提供了以上咪唑并哒嗪类衍生物或其立体异构体、氘代化合物或其药学上可接受的盐或前药在制备蛋白激酶抑制剂中的应用,所述蛋白激酶包括TRK、FLT3、RET、VEGFR2、DDR1中的至少一种。
第三方面,本发明还提供了以上咪唑并哒嗪类衍生物或其立体异构体、氘代化合物或其药学上可接受的盐或前药在制备蛋白激酶介导疾病药物中的应用,所述蛋白激酶包括TRK、FLT3、RET、VEGFR2、DDR1中的至少一种。
在其中一些实施例中,所述蛋白激酶介导疾病为肿瘤,所述肿瘤包括非小细胞肺癌、乳腺癌、结肠癌、前列腺癌、甲状腺癌、恶性黑色素瘤、神经母细胞瘤和乳腺样分泌癌中的至少一种。
第四方面,本发明还提供了一种药用组合物,包括:活性成分和药学上可接受的辅料,所述活性成分包括以上咪唑并哒嗪类衍生物或其立体异构体、氘代化合物或其药学上可接受的盐或前药。
附图说明
图1为实施例1的合成路线图;
图2为实施例2的合成路线图;
图3为实施例5的合成路线图;
图4为实施例6的合成路线图;
图5为对比例7的合成路线图。
具体实施方式
在本发明的描述中,所涉及的化合物及其衍生物均是按照IUPAC(国际纯粹与应用化学联合会)或CAS(化学文摘服务社,位于俄亥俄州哥伦布市)命名系统命名的,具体涉及到的化合物基团作如下阐述与说明:
“酰胺基”是指羰基的碳连接了一个氨基或胺基形成的基团,化学式可表示为-C(O)-NH-。
“脲基”是指尿素两端的氨基氢被取代后形成的基团,化学式可表示为-NH-C(O)-NH-。
“砜基”的化学式表示为-(O)S(O)-。
“亚硫酰基”的化学式表示为-S(O)-。
“磺酰胺基”的化学式可表示为-NH-(O)S(O)-NH-。
“卤基”指的是元素周期表中ⅦA族元素基团,包括氯(Cl)、溴(Br)、碘(I)等。
“氰基”是指碳原子和氮原子通过三键相连接的基团,化学式表示为-CN。
“羟基”是指由一个氧和一个氢形成的基团,化学式表示为-OH。
“氨基”是指由一个氧和一个氮形成的基团,化学式表示为-NH2。
“胺基”是指氨基上的氢被烷基取代形成的基团,例如-CH2-N(CH3)2。
“烷基”指的是一类仅含有碳、氢两种原子的饱和链状烃基,具有直链碳链和/或支链碳链,包括但不限于甲基、乙基、丙基、异丙基、丁基、异丁基、戊基、异戊基、己基等。本发明的烷基的碳原子个数为1-20,优选为1-10,具体实施例中,烷基的碳原子个数为1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19或20。
“烷氧基”指的是一类与氧原子直接键合的烷基,包括但不限于如甲氧基、乙氧基、丙氧基、丁氧基、异丁氧基、叔丁氧基等。本发明的烷氧基的碳原子个数为1-20,优选为1-10,具体实施例中,烷氧基的碳原子个数为1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19或20。
“卤代烷基”是指烷基的氢原子被卤基取代形成的基团,包括但不限于二氟甲基、二氟乙基、三氯甲基或三溴乙基等。本发明的卤代烷基的碳原子个数为1-20,优选为1-10,具体实施例中,卤代烷基的碳原子个数为1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19或20。
“烷基胺基”是指一类与烷基直接键合的胺基,例如-CH2NH2。本发明的烷基胺基的碳原子个数为1-20,优选为1-10,具体实施例中,其碳原子个数为1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19或20。
“羟烷基”是指由烷基和羟基直接键合形成的基团,例如-CH2OH。本发明的羟烷基的碳原子个数为1-20,优选为1-10,具体实施例中,其碳原子个数为1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19或20。
“杂环烷基”指的是分子中含有至少一个杂原子的环烷基,包括但不限于氮杂二环庚烷基、氮杂环丁烷基、二氢吲哚基、吗啉基、派嗪基、哌啶基、吡咯烷基、四氢呋喃基、四氢喹啉基、四氢吲唑基、四氢吲哚基、四氢异喹啉基、四氢吡喃基、四氢喹喔啉基、四氢噻喃基、噻唑烷基、硫代吗啉基、噻吨基、噻恶烷基等。本发明的杂环烷基的碳原子个数为3-20,具体实施例中,其碳原子个数为3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19或20。
“杂芳基”指的是一类分子中含有至少一个杂原子的芳基,包括但不限于苯并呋喃基、噻吩基、苯并噻吩基、苯并咪唑基、苯并恶唑基、苯并噻唑基、苯并吡喃基、呋喃基、咪唑基、吲唑基、吲嗪基、吲哚基、异苯并呋喃基、异吲哚基、异喹啉基、异噻唑基、异恶唑基、萘啶基、噁二唑基、噁嗪基、噁唑基、酞嗪基、蝶啶基、嘌呤基、吡喃基、吡嗪基、吡唑基、哒嗪基、吡啶[3,4-b]吲哚基、吡啶基、嘧啶基、吡咯基、喹嗪基、喹啉基、喹喔啉基、噻二唑基、噻三唑基、噻唑基、噻吩基、三嗪基、三唑基、呫吨基等。本发明的杂芳基的碳原子个数为6-20,具体实施例中,杂芳基的碳原子个数为6、7、8、9、10、11、12、13、14、15、16、17、18、19或20。
“芳基”指的是一类芳香烃上缺少一个氢形成的有机基团,可为单环芳基、多环芳基或稠环芳基,包括但不限于苯基、萘基、蒽基、菲基等。本发明的芳基的碳原子个数为6-20,具体实施例中,芳基的碳原子个数为6、7、8、9、10、11、12、13、14、15、16、17、18、19或20。
“环氧基”是指具有-CH(O)CH-结构的环状基团,本发明的环氧基的碳原子个数为2-20,具体实施例中,其碳原子个数为2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19或20。
为使本发明的目的、技术方案和优点更加清楚明了,下面结合具体实施方式,对本发明进一步详细说明。应该理解,这些描述只是示例性的,而并非要限制本发明的范围。此外,在以下说明中,省略了对公知结构和技术的描述,以避免不必要地混淆本发明的概念。
本发明实施例提供的咪唑并哒嗪类衍生物,既包括如通式(Ⅰ)所示结构的游离形式,也包括其立体异构体、氘代化合物或其药学上可接受的盐或前药:
术语“游离形式”指以非盐形式的化合物。“药学上可接受盐”不仅包括本文所述特定化合物的示例性盐,也包括所有式(Ⅰ)化合物游离形式的典型的药学上可接受的盐。可使用本领域已知技术分离所述化合物特定盐的游离形式。例如,可通过用适当的碱稀水溶液例如NaOH稀水溶液、碳酸钾稀水溶液、稀氨水及碳酸氢钠稀水溶液处理该盐使游离形式再生。游离形式在某些物理性质例如在极性溶剂中溶解度上与其各自盐形式多少有些区别,但是为发明的目的这种酸盐及碱盐在其它药学方面与其各自游离形式相当。
可通过常规化学方法自含有碱性部分或酸性部分的本发明化合物合成本发明的药学上可接受的盐。通常,通过离子交换色谱或通过游离碱和化学计算量或过量的所需盐形式的无机或有机酸在适当溶剂或多种溶剂的组合中反应制备碱性化合物的盐。类似的,通过和适当的无机或有机碱反应形成酸性化合物的盐。
因此,本发明化合物的药学上可接受的盐包括通过碱性本发明化合物和无机或有机酸反应形成的本发明化合物的常规无毒盐。
如果本发明化合物为酸性的,则适当的“药学上可接受的盐”指通过药学上可接受的无毒碱包括无机碱及有机碱制备的盐。
为了使本发明要解决的技术问题、技术方案及有益效果更加清楚明白,以下结合实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。
实施例1
本实施例按照图1所示的合成路线合成了:(R)-N-(3-((4-甲基哌嗪-1-基)甲基)-5-(三氟甲基)苯基)-1-(3-(吡啶-2-基)咪唑[1,2-b]哒嗪-6-基)吡咯烷-3-甲酰胺(命名为XS4-145),具体步骤如下:
步骤1:(R)-1-(3-碘代咪唑[1,2-b]哒嗪-6-基)吡咯烷-3-羧酸甲酯(化合物2)的制备
将6-氯-3-碘代咪唑[1,2-b]哒嗪540mg溶于20mL DMSO溶液,然后添加(R)-吡咯烷-3-羧酸甲酯500mg(3.8mmol)、氟化钾(KF)1.3g(22.8mmol)。将混合物在120℃下搅拌,过夜反应。体系用乙酸乙酯和水萃取2-3次,有机层用无水Na2SO4干燥,过滤并旋干。通过硅胶柱层析纯化粗物质,得到黄色固体260mg(收率36.7%)。
1H NMR(400MHz,Chloroform-d)δ7.65(dd,J=9.8,1.5Hz,1H),7.60(t,J=1.5Hz,1H),6.61(d,J=9.6Hz,1H),3.89–3.79(m,2H),3.78(s,3H),3.72(t,J=7.9Hz,1H),3.61(q,J=8.9,8.3Hz,1H),3.28(p,J=7.3Hz,1H),2.37(q,J=7.1Hz,2H).MS(ESI)m/z 374.1[M+H]+。
步骤2:(R)-1-(3-(吡啶-2-基)咪唑[1,2-b]哒嗪-6-基)吡咯烷-3-羧酸甲酯(化合物4)的制备
将250mg化合物2(0.64mmol)溶于10mL的甲苯溶液中,然后添加2-(三丁基锡)吡啶353mg(0.96mmol),四三苯基磷钯37mg(0.03mmol)。氩气保护,溶液在110℃下搅拌过夜,蒸发至干燥。通过硅胶柱层析纯化相应产物,得到黄色固体40mg(产率19%)。
1H NMR(400MHz,Chloroform-d)δ8.72(d,J=7.9Hz,1H),8.64(d,J=4.1Hz,1H),7.97–7.88(m,2H),7.33–7.26(m,2H),6.54(d,J=9.8Hz,1H),3.77–3.64(m,5H),3.58(q,J=7.3Hz,1H),3.50–3.43(m,1H),3.20(p,J=7.3Hz,1H),2.27(q,J=7.1Hz,2H).MS(ESI)m/z 323.9[M+H]+。
步骤3:(R)-N-(3-((4-甲基哌嗪-1-基)甲基)-5-(三氟甲基)苯基)-1-(3-(吡啶-2-基)咪唑[1,2-b]哒嗪-6-基)吡咯烷-3-甲酰胺(命名为XS4-145)的制备
将40mg化合物4(0.12mmol)和3-(4-甲基哌嗪-1-基)甲基-5-(三氟甲基)苯胺39mg(0.14mmol)置于50mL的双口瓶中,氩气保护,然后抽真空20分钟。将无水四氢呋喃10mL注入瓶中,混合物在-10℃冰浴下搅拌20分钟。缓慢注入0.36mL(0.36mmol)1mol/L的双(三甲基硅)胺基锂(LiHMDS)溶液。将混合物在-10℃下搅拌20分钟,然后移至室温下搅拌10分钟,蒸发至干燥。用乙酸乙酯和水萃取,收集有机层并用无水硫酸钠干燥,过滤并蒸发。通过硅胶柱层析纯化粗产物,得到白色固体50mg(收率73.8%)。
1H NMR(400MHz,DMSO-d6)δ10.58(s,1H),8.73(d,J=8.1Hz,1H),8.64(d,J=4.1Hz,1H),8.17(s,1H),8.08(s,1H),7.97–7.89(m,2H),7.78(s,1H),7.33–7.26(m,2H),6.96(d,J=9.8Hz,1H),3.88–3.81(m,1H),3.78–3.69(m,2H),3.64–3.56(m,1H),3.51(s,2H),3.44–3.40(m,1H),2.43–2.23(m,10H),2.15(s,3H).13C NMR(151MHz,DMSO-d6)δ172.37,152.85,150.03,148.69,141.43,140.33,138.07,137.40,133.23,130.11(q,J=31.7Hz),127.30,125.51(q,J=272.6Hz),126.59,123.15,122.34,120.14,119.90,114.46,110.56,61.77,55.14(2C),52.98(2C),49.93,47.13,46.20,44.57,29.62.HPLCanalysis:MeOH:H2O(83:17),5.68min;purity,95.5%.HRMS(ESI)for C29H31F3N8O[M+H]+:calcd565.2646,found 565.2645。
实施例2
本实施例按照图2所示的合成路线合成了:(S)-N-(3-((4-甲基哌嗪-1-基)甲基)-5-(三氟甲基)苯基)-1-(3-(吡啶-2-基)咪唑[1,2-b]哒嗪-6-基)吡咯烷-3-甲酰胺(命名为XS4-142)。
步骤1:(S)-1-(3-碘代咪唑[1,2-b]哒嗪-6-基)吡咯烷-3-羧酸甲酯(化合物2)的制备
将化合物6-氯-3-碘代咪唑[1,2-b]哒嗪389mg(1.39mmol)溶于10mL DMSO溶液,然后添加(S)-吡咯烷-3-羧酸甲酯150mg(1.16mmol)、氟化钾(KF)807mg(13.9mmol)。将混合物在120℃下搅拌,过夜反应。体系用乙酸乙酯和水萃取2-3次,有机层用无水Na2SO4干燥,过滤并旋干。通过硅胶柱层析纯化粗物质,得到黄色固体400mg(收率88.3%)。
1H NMR(400MHz,Chloroform-d)δ7.63(dd,J=9.8,1.5Hz,1H),7.62(t,J=1.5Hz,1H),6.59(d,J=9.6Hz,1H),3.90–3.80(m,2H),3.78(s,3H),3.73(t,J=7.9Hz,1H),3.59(q,J=8.9,8.3Hz,1H),3.28(p,J=7.3Hz,1H),2.37(q,J=7.1Hz,2H).MS(ESI)m/z 374.2[M+H]+.
步骤2:(S)-1-(3-(吡啶-2-基)咪唑[1,2-b]哒嗪-6-基)吡咯烷-3-羧酸甲酯(化合物4)的制备
化合物4由(S)-1-(3-碘代咪唑[1,2-b]哒嗪-6-基)吡咯烷-3-羧酸甲酯(化合物2)和2-(三丁基锡)吡啶(化合物3)通过Suzuki偶联反应制备,合成方法如实施例1步骤2(产率30.4%)。
1H NMR(400MHz,Chloroform-d)δ8.71(d,J=7.9Hz,1H),8.63(d,J=4.1Hz,1H),7.94–7.87(m,2H),7.33–7.26(m,2H),6.53(d,J=9.8Hz,1H),3.75–3.64(m,5H),3.59(q,J=7.3Hz,1H),3.51–3.43(m,1H),3.21(p,J=7.3Hz,1H),2.29(q,J=7.1Hz,2H).MS(ESI)m/z 323.9[M+H]+.
步骤3:(S)-N-(3-((4-甲基哌嗪-1-基)甲基)-5-(三氟甲基)苯基)-1-(3-(吡啶-2-基)咪唑[1,2-b]哒嗪-6-基)吡咯烷-3-甲酰胺(命名为XS4-142)的制备
化合物XS4-142由(S)-1-(3-(吡啶-2-基)咪唑[1,2-b]哒嗪-6-基)吡咯烷-3-羧酸甲酯(化合物4)和3-(4-甲基哌嗪-1-基)甲基)-5-(三氟甲基)苯胺(化合物5)通过酯的氨解反应制备,合成方法如实施例1步骤3(产率74.5%)。
1H NMR(400MHz,DMSO-d6)δ10.54(s,1H),8.73(d,J=8.1Hz,1H),8.64(d,J=2.7Hz,1H),8.17(s,1H),8.07(s,1H),7.98–7.89(m,2H),7.77(s,1H),7.32–7.27(m,2H),6.98(d,J=9.8Hz,1H),3.88–3.84(m,1H),3.78–3.70(m,2H),3.65–3.58(m,1H),3.51(s,2H),3.43–3.37(m,1H),2.43–2.20(m,10H),2.15(s,3H).13C NMR(151MHz,DMSO-d6)δ172.39,152.85,150.03,148.68,141.43,140.32,138.07,137.41,133.21,129.90(q,J=31.7Hz),127.30,126.58,125.50(q,J=272.6Hz),123.17,122.35,120.16,119.91,114.50,110.57,61.77,55.13(2C),52.97(2C),49.92,47.13,46.19,44.57,29.62.HPLCanalysis:MeOH:H2O(83:17),5.79min;purity,100.0%.HRMS(ESI)for C29H31F3N8O[M+H]+:calcd 565.2646,found 565.2644。
实施例3
本实施例合成了:(R)-N-(3-(4-甲基-1H-咪唑-1-基)-5-(三氟甲基)苯基)-1-(3-(吡啶-2-基)咪唑[1,2-b]哒嗪-6-基)吡咯烷-3-甲酰胺(命名为XS4-158)。
合成方法与实施例1的基本相同,由(R)-1-(3-(吡啶-2-基)咪唑[1,2-b]哒嗪-6-基)吡咯烷-3-羧酸甲酯(实施例1化合物4)和3-(4-甲基-1H-咪唑-1-基)-5-(三氟甲基)苯胺通过酯的氨解反应制备,产率78.2%。
1H NMR(400MHz,DMSO-d6)δ10.76(s,1H),8.73(d,J=8.1Hz,1H),8.64(d,J=4.6Hz,1H),8.20(s,1H),8.17(s,1H),8.09(s,1H),8.00–7.88(m,3H),7.69(s,1H),7.46(s,1H),7.34–7.23(m,1H),6.97(d,J=9.8Hz,1H),3.91–3.82(m,1H),3.82–3.76(m,1H),3.75–3.68(m,1H),3.66–3.58(m,1H),3.43(t,J=7.1Hz,1H),2.46–2.36(m,1H),2.35–2.24(m,1H),2.17(s,3H).13C NMR(151MHz,DMSO-d6)δ172.72,152.79,150.00,148.69,141.65,139.34,138.48,138.06,137.35,135.42,133.24,131.54(q,J=32.1Hz),127.29,126.56,124.94(q,J=272.9Hz),122.31,119.87,114.65,114.30,113.73,111.82,110.47,49.82,47.07,46.09,44.63,13.97.HPLC analysis:MeOH:H2O(80:20),7.45min;purity,98.9%.HRMS(ESI)for C27H23F3N8O[M+H]+:calcd 533.2020,found 533.2028。
实施例4
本实施例合成了:(R)-N-(4-((4-甲基哌嗪-1-基)甲基)-3-(三氟甲基)苯基)-1-(3-(吡啶-2-基)咪唑[1,2-b]哒嗪-6-基)吡咯烷-3-甲酰胺(命名为XS5-6)。
合成方法与实施例1的基本相同,由(R)-1-(3-(吡啶-2-基)咪唑[1,2-b]哒嗪-6-基)吡咯烷-3-羧酸甲酯(实施例1化合物4)和4-((4-甲基哌嗪-1-基)甲基)-3-(三氟甲基)苯胺通过酯的氨解反应制备,产率88.6%。
1H NMR(400MHz,Chloroform-d)δ8.66(d,J=4.7Hz,1H),8.58(d,J=8.0Hz,1H),8.48(s,1H),8.35(s,1H),7.93(s,1H),7.84(d,J=8.7Hz,1H),7.79–7.73(m,2H),7.70(d,J=7.6Hz,1H),7.20(t,J=6.4Hz,1H),6.50(d,J=9.1Hz,1H),3.78–3.70(m,2H),3.69–3.61(m,3H),3.46(q,J=8.5Hz,1H),3.21–3.10(m,1H),2.65–2.34(m,10H),2.31(s,3H).13C NMR(151MHz,DMSO-d6)δ172.21,152.83,150.02,148.71,138.60,138.07,137.37,133.24,132.19,131.84,128.04(q,J=29.7Hz),127.30,126.58,125.66(q,J=274.3Hz),122.97,122.31,119.88,116.57,110.51,57.88,55.19(2C),53.14(2C),49.93,47.13,46.19,44.54,29.64.HPLC analysis:MeOH:H2O(85:15),5.44min;purity,99.6%.HRMS(ESI)forC29H31F3N8O[M+H]+:calcd 565.2646,found 565.2659。
实施例5
本实施例按照图3所示的合成路线合成了:(R)-1-(4-氯-3-(三氟甲基)苯基)-3-(1-(3-(吡啶-2-基)咪唑[1,2-b]哒嗪-6-基)吡咯烷-3-基)脲(命名为XS5-3),具体如下:
步骤1:苯基(4-氯-3-(三氟甲基)苯基)氨基甲酸酯(化合物3)的制备
将化合物1 200mg(1.02mmol)溶于20mL的四氢呋喃溶液中,然后添加氯甲酸苯酯192mg(1.22mmol),DIPEA197mg(1.53mmol)。混合物加热回流,过夜反应。旋干反应体系,粗产品无需后处理,直接用于下一步反应。
步骤2:叔丁基(R)-(1-(3-碘代咪唑[1,2-b]哒嗪-6-基)吡咯烷-3-基)氨基甲酸酯(化合物5)的制备
由6-氯-3-碘代咪唑[1,2-b]哒嗪(实施例1化合物1)和3-(Boc-氨基)吡咯烷通过亲核取代反应制备,产率55.9%。
1H NMR(400MHz,Chloroform-d)δ7.64(dd,J=9.8,1.8Hz,1H),7.60(d,J=1.8Hz,1H),6.57(dd,J=9.8,1.8Hz,1H),4.41(s,1H),3.83(dd,J=11.2,6.0Hz,1H),3.74–3.57(m,2H),3.45(dd,J=11.2,4.3Hz,1H),2.44–2.24(m,1H),2.04(dd,J=12.7,6.5Hz,1H),1.48(s,9H).MS(ESI)m/z 430.2[M+H]+。
步骤3:(R)-1-(3-(吡啶-2-基)咪唑[1,2-b]哒嗪-6-基)吡咯烷-3-胺(化合物8)的制备
第一步:将化合物5 500mg(1.1mmol)溶于10mL甲苯溶液中,依次添加2-(三丁基锡)吡啶600mg(1.63mmol),四三苯基磷钯67mg(0.06mmol)。氩气保护,溶液在110℃下搅拌过夜,蒸发至干燥。通过硅胶柱层析纯化相应产物,得到黄色固体60mg(产率14%)。
第二步:将60mg上述黄色固体溶解在10mL DCM中,然后添加2mL三氟乙酸,体系在室温下搅拌2h并蒸发至干燥。然后用饱和NaHCO3溶液洗涤,DCM萃取。有机层用无水Na2SO4干燥,过滤并蒸发。通过硅胶柱层析纯化粗物质,得到黄色固体的最终化合物40mg(收率89.2%)。
1H NMR(400MHz,Chloroform-d)δ8.72–8.63(m,2H),8.37(s,1H),7.86–7.76(m,2H),7.21(t,J=6.3Hz,1H),6.64(d,J=10.2Hz,1H),3.92–3.82(m,1H),3.78–3.63(m,3H),3.52–3.44(m,1H),2.45–2.34(m,1H),2.08(d,J=8.4Hz,2H).MS(ESI)m/z 281.0[M+H]+.
步骤4:(R)-1-(4-氯-3-(三氟甲基)苯基)-3-(1-(3-(吡啶-2-基)咪唑[1,2-b]哒嗪-6-基)吡咯烷-3-基)脲(命名为XS5-3)的制备
将58mg化合物3溶解在10mL甲苯溶液中,添加化合物8 40mg(0.14mmol)。将混合物在100℃下搅拌,过夜反应。将反应体系旋干,通过硅胶柱层析纯化粗产物,得到白色固体56mg(收率80%)。
实施例6
本实施例按照图4所示的合成路线合成了:(R)-1-(咪唑[1,2-b]哒嗪-6-基)-N-(4-(4-甲基哌嗪-1-基)甲基)-3-(三氟甲基)苯基)吡咯烷-3-甲酰胺(命名为XS5-16),具体如下:
步骤1:(R)-1-(3-碘代咪唑并[1,2-b]哒嗪-6-基)-N-(4-((4-甲基哌嗪-1-基)甲基)-3-(三氟甲基)苯基)吡咯烷-3-甲酰胺(化合物3)的制备
参考实施例1步骤3的合成方法,由(R)-1-(3-碘代咪唑[1,2-b]哒嗪-6-基)吡咯烷-3-羧酸甲酯和4-(4-甲基哌嗪-1-基)甲基-5-(三氟甲基)苯胺通过酯的氨解反应制备,产率85.9%。
1H NMR(400MHz,Chloroform-d)δ8.00(s,1H),7.84(s,1H),7.83–7.72(m,2H),7.64(d,J=9.7Hz,1H),7.60(s,1H),6.59(d,J=9.7Hz,1H),3.94–3.77(m,3H),3.69–3.55(m,3H),3.25(t,J=7.4Hz,1H),2.58–2.38(m,10H),2.31(s,3H).MS(ESI)m/z 614.2[M+H]+。
步骤2:(R)-1-(咪唑[1,2-b]哒嗪-6-基)-N-(4-(4-甲基哌嗪-1-基)甲基)-3-(三氟甲基)苯基)吡咯烷-3-甲酰胺(命名为XS5-16)的制备
将化合物3 65mg(0.11mmol)溶解在10mL甲醇溶液中,添加7mg 10%钯(碳)。通入氢气,在室温下搅拌混合物,过夜反应。过滤混合物并蒸发至干燥。通过硅胶柱层析纯化粗产物,得到白色固体38mg(收率73.3%)。
1H NMR(400MHz,Chloroform-d)δ8.21(s,1H),7.82(s,1H),7.82–7.71(m,2H),7.69(t,J=4.2Hz,2H),7.53(s,1H),6.57(d,J=9.8Hz,1H),3.84–3.70(m,3H),3.63(s,2H),3.52(q,J=8.2Hz,1H),3.27–3.15(m,1H),2.62–2.34(m,10H),2.31(s,3H).13C NMR(151MHz,DMSO-d6)δ172.18,152.94,138.61,136.07,132.15,131.83,131.47,128.03(q,J=29.6Hz),126.12,125.66(q,J=274.4Hz),122.97,116.60,116.52,110.66,57.87,55.18(2C),53.14(2C),49.94,47.01,46.19,44.42,29.41.HPLC analysis:MeOH:H2O(70:30),20.32min;purity,100.0%.HRMS(ESI)for C24H28F3N7O[M+H]+:calcd 488.2380,found488.2393.
实施例7
本实施例按照图5所示的合成路线合成了:(R)-N-(4-(4-甲基哌嗪-1-基)甲基)-3-(三氟甲基)苯基)-1-(3-(吡啶-3-基)咪唑[1,2-b]哒嗪-6-基)吡咯烷-3-甲酰胺(命名为XS5-25),具体如下:
将化合物1 80mg(0.13mmol)和化合物2 39mg(0.19mmol)溶解在二氧六环(10mL)和H2O(2mL)中,依次添加[1,1'-双(二苯基膦基)二茂铁]二氯化钯10mg(0.013mmol)、碳酸钾36mg(0.26mmol)。氩气保护,混合物在80℃下搅拌,过夜反应。旋干反应体系,通过硅胶柱层析纯化相应产物,得到白色固体60mg(收率81.3%)。
1H NMR(400MHz,Chloroform-d)δ9.50(s,1H),8.54(s,1H),8.37(d,J=8.1Hz,1H),8.20(s,1H),7.92(s,1H),7.86(s,1H),7.76(q,J=9.5Hz,3H),7.40(t,J=6.3Hz,1H),6.67(d,J=9.8Hz,1H),3.92–3.78(m,3H),3.67–3.56(m,3H),3.31–3.21(m,1H),2.56–2.36(m,10H),2.30(s,3H).13C NMR(151MHz,DMSO-d6)δ172.21,152.83,148.08,146.89,138.60,137.83,132.76,132.16,131.82,131.30,128.03(q,J=29.8Hz),126.50,126.14,125.66(q,J=274.3Hz),124.12,124.10,122.98,116.58,110.74,57.87,55.17(2C),53.12(2C),49.93,47.10,46.18,44.47,29.56.HPLC analysis:MeOH:H2O(75:25),14.38min;purity,97.2%.HRMS(ESI)for C29H31F3N8O[M+H]+:calcd 565.2646,found 565.2635。
实施例8
本实施例合成了:(R)-1-(3-(6-氨基吡啶-3-基)咪唑[1,2-b]哒嗪-6-基)-N-(4-((4-甲基哌嗪-1-基)甲基)-3-(三氟甲基)苯基)吡咯烷-3-甲酰胺(命名为XS5-31),具体如下:
第一步:将(R)-1-(3-碘代咪唑[1,2-b]哒嗪-6-基)-N-(4-(4-甲基哌嗪-1-基)甲基)-3-(三氟甲基)苯基)吡咯烷-3-甲酰胺150mg(0.24mmol)和(5-(4,4,5,5-四甲基-1,3,2-二氧苯甲醛-2-基)吡啶-2-基)氨基甲酸叔丁酯154mg(0.48mmol)溶解在二氧六环(10mL)和H2O(2mL)中,依次添加[1,1'-双(二苯基膦基)二茂铁]二氯化钯18mg(0.024mmol)、碳酸钾66mg(0.48mmol)。氩气保护,混合物在80℃下搅拌,过夜反应。旋干反应体系,通过硅胶柱层析纯化相应产物,得到黄色固体100mg。
第二步:将上述100mg黄色固体溶于10mL的二氯甲烷溶液中,然后加入2mL的三氟乙酸溶液。混合物室温下搅拌2小时后,旋干反应体系。用饱和碳酸氢钠和DCM萃取,收集有机层,用无水硫酸钠干燥,过滤并真空干燥有机层。通过硅胶柱层析纯化相应产物,得到黄色固体70mg。(两步产率50.3%)
1H NMR(400MHz,DMSO-d6)δ10.48(s,1H),8.80(d,J=2.3Hz,1H),8.13–8.06(m,2H),7.86–7.76(m,3H),7.65(d,J=8.5Hz,1H),6.82(d,J=9.8Hz,1H),6.55(d,J=8.7Hz,1H),6.08(s,2H),3.79(dd,J=10.5,7.8Hz,1H),3.71–3.60(m,2H),3.57–3.49(m,3H),3.36–3.31(m,1H),2.44–2.18(m,10H),2.14(s,3H).13C NMR(151MHz,DMSO-d6)δ172.20,159.07,152.64,145.82,138.59,136.71,135.22,132.15,131.82,128.84,127.84(q,J=29.7Hz),126.25,125.73,123.84(q,J=274.3Hz),122.95,116.56,114.50,109.20,108.09,57.87,55.17(2C),53.11(2C),49.94,47.04,46.16,44.49,29.46.HPLC analysis:MeOH:H2O(90:10),4.87min;purity,99.7%.HRMS(ESI)for C29H32F3N9O[M+H]+:calcd580.2755,found 580.2749。
实施例9
本实施例合成了:(R)-1-(3-(1H-吡唑-4-基)咪唑[1,2-b]哒嗪-6-基)-N-(4-((4-甲基哌嗪-1-基)甲基)-3-(三氟甲基)苯基)吡咯烷-3-甲酰胺(命名为XS5-10),具体如下:
参考实施例7的合成方法,由(R)-1-(3-碘代咪唑并[1,2-b]哒嗪-6-基)-N-(4-((4-甲基哌嗪-1-基)甲基)-3-(三氟甲基)苯基)吡咯烷-3-甲酰胺(实施例7化合物1)和4-吡唑硼酸频哪醇酯通过Suzuki偶联反应制备,产率40.0%。
1H NMR(600MHz,DMSO-d6)δ13.04(s,1H),10.48(s,1H),8.52–8.15(m,2H),8.10(d,J=2.2Hz,1H),7.84(d,J=9.7Hz,1H),7.83–7.80(m,1H),7.80(s,1H),7.67(d,J=8.5Hz,1H),6.83(d,J=9.8Hz,1H),3.85(dd,J=10.3,7.8Hz,1H),3.76–3.67(m,2H),3.63–3.56(m,2H),3.54(s,2H),2.43–2.22(m,10H),2.15(s,3H).13C NMR(151MHz,DMSO-d6)δ172.24,152.96,138.60,136.06,132.18,131.85,130.12,128.26,127.85(q,J=29.6Hz),126.09,125.66(q,J=274.2Hz),122.98,121.98,116.61,110.14,108.85,57.87,55.17(2C),53.13(2C),49.94,47.08,46.18,44.53,29.55.HPLC analysis:MeOH:H2O(70:30),16.63min;purity,100.0%.HRMS(ESI)for C27H30F3N9O[M+H]+:calcd 554.2598,found554.2607。
实施例10
本实施例合成了:(R)-1-(3-(1-甲基-1H-吡唑-4-基)咪唑[1,2-b]哒嗪-6-基)-N-(4-(4-甲基哌嗪-1-基)甲基)-3-(三氟甲基)苯基)吡咯烷-3-甲酰胺(命名为XS5-9),具体如下:
参考实施例7的合成方法,由(R)-1-(3-碘代咪唑并[1,2-b]哒嗪-6-基)-N-(4-((4-甲基哌嗪-1-基)甲基)-3-(三氟甲基)苯基)吡咯烷-3-甲酰胺(实施例7化合物1)和1-甲基-4-(4,4,5,5-四甲基-1,3,2-二氧杂戊硼烷-2-基)-1H-吡唑通过Suzuki偶联反应制备,产率75.9%。
1H NMR(600MHz,DMSO-d6)δ10.49(s,1H),8.36(s,1H),8.12(s,1H),8.11(d,J=2.2Hz,1H),7.84(d,J=9.8Hz,1H),7.82(dd,J=8.8,2.2Hz,1H),7.77(s,1H),7.67(d,J=8.5Hz,1H),6.83(d,J=9.8Hz,1H),3.93(s,3H),3.85(dd,J=10.4,7.8Hz,1H),3.76–3.68(m,2H),3.62–3.56(m,1H),3.54(s,2H),3.40–3.38(m,1H),2.48–2.18(m,10H),2.15(s,3H).13C NMR(151MHz,DMSO-d6)δ172.31,152.98,138.63,136.45,136.07,132.16,131.84,128.22,128.03(q,J=29.6Hz),127.82,126.11,125.67(q,J=274.3Hz),122.96,121.68,116.60,110.88,108.90,57.88,55.19(2C),53.14(2C),49.92,47.05,46.20,44.53,39.18,29.62.HPLC analysis:MeOH:H2O(70:30),14.62min;purity,99.2%.HRMS(ESI)forC28H32F3N9O[M+H]+:calcd 568.2755,found 568.2759。
实施例11
本实施例合成了:(R)-1-(3-(1-(2-羟乙基)-1H-吡唑-4-基)咪唑[1,2-b]哒嗪-6-基)-N-)4-(4-甲基哌嗪-1-基)甲基)-3-(三氟甲基)苯基)吡咯烷-3-甲酰胺(命名为XS5-11),具体如下:
参考实施例7的合成方法,由(R)-1-(3-碘代咪唑并[1,2-b]哒嗪-6-基)-N-(4-((4-甲基哌嗪-1-基)甲基)-3-(三氟甲基)苯基)吡咯烷-3-甲酰胺(实施例7化合物1)和1-(2-羟基乙基)-1H-吡唑-4-硼酸频哪醇酯通过Suzuki偶联反应制备,产率57.7%。
1H NMR(400MHz,Chloroform-d)δ9.04(s,1H),7.91(d,J=8.4Hz,2H),7.85(d,J=10.0Hz,2H),7.74(d,J=8.5Hz,1H),7.39(s,1H),7.33(d,J=9.6Hz,1H),6.20(d,J=9.7Hz,1H),4.27(d,J=5.6Hz,2H),4.10(d,J=4.8Hz,2H),3.63(s,2H),3.56–3.46(m,3H),3.25–3.15(m,2H),2.57–2.34(m,10H),2.31(s,3H).13C NMR(151MHz,DMSO-d6)δ172.32,152.95,138.61,136.45,136.04,132.16,131.85,128.14,128.04(q,J=29.6Hz),127.79,126.08,125.66(q,J=274.3Hz),122.98,121.78,116.58,110.51,108.90,60.55,57.87,55.17(2C),54.63,53.12(2C),49.91,47.01,46.18,44.52,29.60.HPLC analysis:MeOH:H2O(70:30),10.69min;purity,100.0%.HRMS(ESI)for C29H34F3N9O2[M+H]+:calcd598.2860,found 598.2869。
实施例12
本实施例合成了:(R)-N-(4-(4-甲基哌嗪-1-基)甲基)-3-(三氟甲基)苯基)-1-(3-(1-(四氢-2H-吡喃-4-基)-1H-吡唑-4-基)咪唑[1,2-b]哒嗪-6-基)吡咯烷-3-甲酰胺(命名为XS5-12),具体如下:
参考实施例7的合成方法,由(R)-1-(3-碘代咪唑并[1,2-b]哒嗪-6-基)-N-(4-((4-甲基哌嗪-1-基)甲基)-3-(三氟甲基)苯基)吡咯烷-3-甲酰胺(实施例7化合物1)和1-(四氢吡喃-4-基)-1H-吡唑-4-硼酸频哪醇酯通过Suzuki偶联反应制备,产率62.6%。
1H NMR(600MHz,DMSO-d6)δ10.48(s,1H),8.46(s,1H),8.19(s,1H),8.11(d,J=2.2Hz,1H),7.83(d,J=9.7Hz,1H),7.81(dd,J=8.6,2.2Hz,1H),7.78(s,1H),7.67(d,J=8.5Hz,1H),6.82(d,J=9.7Hz,1H),4.53–4.45(m,1H),3.95(d,J=11.7Hz,2H),3.88–3.83(m,1H),3.75–3.67(m,2H),3.62–3.57(m,1H),3.53(s,2H),3.51–3.44(m,3H),2.50–2.19(m,10H),2.15(s,3H),2.06–1.94(m,4H).13C NMR(151MHz,DMSO-d6)δ172.23,152.93,138.61,136.30,136.06,132.17,131.85,128.24,127.86(q,J=29.7Hz),126.09,125.66(q,J=274.4Hz),125.09,122.94,121.70,116.58,110.51,108.90,66.34,57.87,57.61(2C),55.17(2C),53.12(2C),49.94,46.98,46.18,44.52,33.38(2C),29.47.HPLCanalysis:MeOH:H2O(70:30),22.85min;purity,99.2%.HRMS(ESI)for C32H38F3N9O2[M+H]+:calcd 638.3173,found 638.3175。
实施例13化合物对TRKs激酶的IC50测试
激酶活性检测:应用Z′-LYTETM技术(采用荧光进行检测、酶偶联形式,以磷酸化和非磷酸化多肽对蛋白水解切割的敏感性差异为基础),采用荧光共振能量转移(FRET)原理,使用Z′-LYTETM FRET肽类底物,二级反应检测化合物对TRKs(TRKA,TRKB,TRKC,TRKAG667C)激酶(美国生命技术公司,PV3144,PV3616,PV3617)的抑制活性。
酶促反应:384孔板中,加入5μL酶-底物体系[50mM 4-羟乙基哌嗪乙磺酸(HEPES)pH 7.5,0.01%BRIJ-35,10mM氯化镁(MgCl2),1mM乙二醇双(2-氨基乙基醚)四乙酸(EGTA),2μM Tyr 01肽底物],利用echo520超微量液体移液系统转入5nL待测化合物(浓度梯度),室温震荡10-20min后,利用echo520超微量液体移液系统分别转入200nL,12.5nL,25nL ATP(终浓度分别为400uM,25uM,50uM),震荡混匀后离心,30℃避光反应1.5h。
检测反应:每孔加入2.5μL反应液(Development Solution)(1:128稀释)37℃避光孵育1h,然后加入5μL终止液(Stop Reagent)。
读板:多标记微孔板检测仪(Perkin Elmer EnVision Multimode Plate Reader)检测荧光信号(激发光波长为400nm,发射光波长为460nm、535nm)。
计算:通过全活性孔和对照信号孔计算出每个孔的抑制率,数据分析方法如下:
磷酸化比率=1–{(发射比×F100%–C100%)/[C 0%–C 100%+发射比×(F100%–F0%)]}×100,
抑制率=100×(1–化合物磷酸化比率/阴性对照磷酸化比率)。
IC50值采用医学绘图软件(GraphPad Prism5.0)计算求得。
激酶活性测试结果如表1所示。从表1数据可以看出,本发明实施例的咪唑并哒嗪类化合物对野生型TRKs激酶及xDFG突变的TRK激酶有较强的抑制活性。
表1化合物激酶活性测试结果(IC50:nM)
实施例14基于Ba/F3-TRKs稳定株的细胞增殖抑制活性研究
本实验使用的BaF3细胞(小鼠前B细胞)购自日本细胞库,BaF3-CD74-NTRK1、BaF3-ETV6-NTRK2、BaF3-ETV6-NTRK3、BaF3-CD74-NTRK1单克隆稳定株均由本实验室构建,并通过阳性药活性、蛋白表达及基因测序等实验鉴定完全正确。
稳定株构建的简要步骤如下:构建携带CD74-NTRK1、ETV6-NTRK2、ETV6-NTRK3等基因的pCDNA3.1(+)质粒载体;使用Cell LineKit V试剂盒将质粒电转入Ba/F3细胞;电转48小时后,加入终浓度为1000μg/ml的遗传霉素(G418)筛选两周并撤去白介素3(IL3)继续筛选,获得多克隆稳定株;然后通过极限稀释法挑选单克隆;进而使用阳性药、蛋白免疫印迹(Western Blot,WB)、基因测序对稳定株进行鉴定;鉴定完全正确的单克隆即可用于抑制剂的细胞增殖抑制活性研究。
细胞增殖抑制活性研究:将对数生长期的细胞按8000-12000个/孔接种到96孔板,次日加入不同浓度的抑制剂(0-10μM),继续培养72小时;然后每孔加入10μL CellCounting Kit-8细胞计数试剂(CCK-8试剂),继续孵育1-3小时;接着用超级酶标仪测定其在450nm及650nm的吸光值。使用医学绘图软件(GraphPad Prism 8.0.0)计算半数抑制浓度(IC50)。
测试结果如表2所示。从表2数据可以看出,本发明实施例的咪唑并哒嗪类化合物对Ba/F3-TRKs稳定株的细胞增殖有较强的抑制活性。
表2化合物对细胞增值的抑制活性测试结果(IC50:nM)
实施例15化合物SX5-6对FLT3、RET、VEGFR2激酶的IC50测试
激酶活性检测:应用Z′-LYTETM技术(采用荧光进行检测、酶偶联形式,以磷酸化和非磷酸化多肽对蛋白水解切割的敏感性差异为基础),采用荧光共振能量转移(FRET)原理,使用Z′-LYTETM FRET肽类底物,二级反应检测化合物对FLT3,RET,VEGFR2激酶(美国生命技术公司,PV3144,PV3616,PV3617)的抑制活性。
酶促反应:384孔板中,加入5μL酶-底物体系[50mM 4-羟乙基哌嗪乙磺酸(HEPES)pH 7.5,0.01%BRIJ-35,10mM氯化镁(MgCl2),1mM乙二醇双(2-氨基乙基醚)四乙酸(EGTA),2μM Tyr 01肽底物],利用echo520超微量液体移液系统转入5nL待测化合物(浓度梯度),室温震荡10-20min后,利用echo520超微量液体移液系统分别转入200nL,12.5nL,25nL ATP(终浓度分别为400uM,25uM,50uM),震荡混匀后离心,30℃避光反应1.5h。
检测反应:每孔加入2.5μL反应液(Development Solution)(1:128稀释)37℃避光孵育1h,然后加入5μL终止液(Stop Reagent)。
读板:多标记微孔板检测仪(Perkin Elmer EnVision Multimode Plate Reader)检测荧光信号(激发光波长为400nm,发射光波长为460nm、535nm)。
计算:通过全活性孔和对照信号孔计算出每个孔的抑制率,数据分析方法如下:
磷酸化比率=1–{(发射比×F100%–C100%)/[C 0%–C 100%+发射比×(F100%–F0%)]}×100;
抑制率=100×(1–化合物磷酸化比率/阴性对照磷酸化比率)。
IC50值采用医学绘图软件(GraphPad Prism5.0)计算求得。
激酶活性测试结果如表3所示。
表3化合物XS5-6的激酶活性测试结果(IC50:nM)
实施例16基于Ba/F3-TRKs稳定株的耐药细胞增殖抑制活性研究
本实验使用的BaF3细胞(小鼠前B细胞)购自日本细胞库,BaF3-CD74-NTRK1-G667C、BaF3-CD74-NTRK1-G595R、BaF3-CD74-NTRK1-G667A、BaF3-CD74-NTRK1-G667S、BaF3-CD74-NTRK1-V573M、BaF3-ETV6-NTRK3-G696C、BaF3-ETV6-NTRK3-G696A、BaF3-ETV6-NTRK3-G696S、BaF3-ETV6-NTRK3-G623R、BaF3-ETV6-NTRK3-G623E单克隆稳定株均由本实验室构建,并通过阳性药活性、蛋白表达及基因测序等实验鉴定完全正确。
稳定株构建的简要步骤如下:构建携带BaF3-CD74-NTRK1-G667C、BaF3-CD74-NTRK1-G595R、BaF3-CD74-NTRK1-G667A、BaF3-CD74-NTRK1-G667S、BaF3-CD74-NTRK1-V573M、BaF3-ETV6-NTRK3-G696C、BaF3-ETV6-NTRK3-G696A、BaF3-ETV6-NTRK3-G696S、BaF3-ETV6-NTRK3-G623R、BaF3-ETV6-NTRK3-G623E等基因的pCDNA3.1(+)质粒载体;使用CellLineKit V试剂盒将质粒电转入Ba/F3细胞;电转48小时后,加入终浓度为1000μg/ml的遗传霉素(G418)筛选两周并撤去白介素3(IL3)继续筛选,获得多克隆稳定株;然后通过极限稀释法挑选单克隆;进而使用阳性药、蛋白免疫印迹(Western Blot,WB)、基因测序对稳定株进行鉴定;鉴定完全正确的单克隆即可用于抑制剂的细胞增殖抑制活性研究。
细胞增殖抑制活性研究:将对数生长期的细胞按8000-12000个/孔接种到96孔板,次日加入不同浓度的抑制剂(0-10μM),继续培养72小时;然后每孔加入10μL CellCounting Kit-8细胞计数试剂(CCK-8)试剂,继续孵育1-3小时;接着用超级酶标仪测定其在450nm及650nm的吸光值。使用医学绘图软件(GraphPad Prism 8.0.0)计算半数抑制浓度(IC50)。
测试结果如表4所示,本发明实施例的咪唑并哒嗪类化合物对Ba/F3-TRKs稳定株的耐药细胞增殖有很强的抑制活性。
表4化合物XS5-6对细胞增殖的抑制活性测试结果(IC50:nM)
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明的保护范围之内。
Claims (10)
2.根据权利要求1所述的咪唑并哒嗪类衍生物或其立体异构体、氘代化合物或其药学上可接受的盐或前药,其特征在于,R1选自氢、卤基、氰基、羟基、C1-C20烷基、C1-C20烷氧基、C1-C20卤代烷基中的一种;和/或
R2选自氢、卤基、氰基、羟基、C1-C20卤代烷基、取代或未取代的杂环烷基、取代或未取代的杂芳基中的一种,所述杂环烷基或所述杂芳基中的杂原子个数为1-3,所述杂环烷基具有5-10元环结构,所述杂环烷基中的杂原子为N、O或S,所述杂芳基具有5-6元环结构,所述杂芳基中的杂原子为N;和/或
R3选自氢、卤基、氰基、羟基、C1-C20烷基、C1-C20卤代烷基、C1-C20烷氧基、取代或未取代的杂环烷基、取代或未取代的杂芳基中的一种,所述杂环烷基或所述杂芳基中的杂原子个数为1-3,所述杂原子为N,所述杂环烷基或所述杂芳基具有5-10元环结构。
3.根据权利要求2所述的咪唑并哒嗪类衍生物或其立体异构体、氘代化合物或其药学上可接受的盐或前药,其特征在于,L选自酰胺或脲基;和/或
R1选自氢、卤基、氰基、羟基、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基中的一种;和/或
R2选自氢、卤基、氰基、羟基、C1-C4卤代烷基、取代或未取代的N-杂环烷基、取代或未取代的N-杂芳基、-(CH2)xR6中的至少一种,所述N-杂环烷基和所述N-杂芳基具有5-6元环结构,x为1-5的整数,R6为C1-C5烷基取代或未取代的吗啉基、吡咯烷基、哌啶基或哌嗪基;和/或
R3选自氢、卤基、氰基、羟基、烷基、卤代烷基、烷氧基、取代或未取代的N-杂环烷基、取代或未取代的N-杂芳基、-(CH2)xR6中的至少一种,所述N-杂环烷基和所述N-杂芳基具有5-6元环结构,x为1-5的整数,R6为C1-C5烷基取代或未取代的吗啉基、吡咯烷基、哌啶基或哌嗪基;和/或
7.权利要求1至6任一项所述的咪唑并哒嗪类衍生物或其立体异构体、氘代化合物或其药学上可接受的盐或前药在制备蛋白激酶抑制剂中的应用,所述蛋白激酶包括TRK、FLT3、RET、VEGFR2、DDR1中的至少一种。
8.权利要求1至6任一项所述的咪唑并哒嗪类衍生物或其立体异构体、氘代化合物或其药学上可接受的盐或前药在制备蛋白激酶介导疾病药物中的应用,所述蛋白激酶包括TRK、FLT3、RET、VEGFR2、DDR1中的至少一种。
9.根据权利要求8所述的应用,其特征在于,所述蛋白激酶介导疾病为肿瘤,所述肿瘤包括非小细胞肺癌、乳腺癌、结肠癌、前列腺癌、甲状腺癌、恶性黑色素瘤、神经母细胞瘤和乳腺样分泌癌中的至少一种。
10.一种药用组合物,其特征在于,包括:活性成分和药学上可接受的辅料,所述活性成分包括权利要求1至6任一项所述的咪唑并哒嗪类衍生物或其立体异构体、氘代化合物或其药学上可接受的盐或前药。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210804522.1A CN114989176A (zh) | 2022-07-08 | 2022-07-08 | 咪唑并哒嗪类衍生物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210804522.1A CN114989176A (zh) | 2022-07-08 | 2022-07-08 | 咪唑并哒嗪类衍生物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114989176A true CN114989176A (zh) | 2022-09-02 |
Family
ID=83020812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210804522.1A Pending CN114989176A (zh) | 2022-07-08 | 2022-07-08 | 咪唑并哒嗪类衍生物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114989176A (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120065184A1 (en) * | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
CN104024261A (zh) * | 2011-11-01 | 2014-09-03 | 霍夫曼-拉罗奇有限公司 | 咪唑并哒嗪化合物 |
CN104520300A (zh) * | 2012-06-04 | 2015-04-15 | 第一三共株式会社 | 作为激酶抑制剂的咪唑并[1,2-b]哒嗪衍生物 |
WO2019120267A1 (zh) * | 2017-12-22 | 2019-06-27 | 成都先导药物开发股份有限公司 | 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂 |
WO2021042890A1 (zh) * | 2019-09-04 | 2021-03-11 | 罗欣药业(上海)有限公司 | 杂环化合物及其作为Trk激酶抑制剂的应用 |
WO2021098745A1 (zh) * | 2019-11-18 | 2021-05-27 | 上海轶诺药业有限公司 | 一类蛋白受体激酶抑制剂的制备和应用 |
CN112979654A (zh) * | 2019-12-16 | 2021-06-18 | 成都倍特药业有限公司 | 杂芳基稠环化合物、其制备方法及应用 |
CN113861198A (zh) * | 2020-06-30 | 2021-12-31 | 上海医药集团股份有限公司 | 咪唑并[4,5-b]吡嗪类化合物、其制备方法及应用 |
WO2022095909A1 (zh) * | 2020-11-03 | 2022-05-12 | 上海瑶琪生物科技有限公司 | 用作ntrk激酶抑制剂的化合物及其应用 |
-
2022
- 2022-07-08 CN CN202210804522.1A patent/CN114989176A/zh active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120065184A1 (en) * | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
CN104024261A (zh) * | 2011-11-01 | 2014-09-03 | 霍夫曼-拉罗奇有限公司 | 咪唑并哒嗪化合物 |
CN104520300A (zh) * | 2012-06-04 | 2015-04-15 | 第一三共株式会社 | 作为激酶抑制剂的咪唑并[1,2-b]哒嗪衍生物 |
WO2019120267A1 (zh) * | 2017-12-22 | 2019-06-27 | 成都先导药物开发股份有限公司 | 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂 |
CN109956957A (zh) * | 2017-12-22 | 2019-07-02 | 成都先导药物开发股份有限公司 | 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂 |
WO2021042890A1 (zh) * | 2019-09-04 | 2021-03-11 | 罗欣药业(上海)有限公司 | 杂环化合物及其作为Trk激酶抑制剂的应用 |
WO2021098745A1 (zh) * | 2019-11-18 | 2021-05-27 | 上海轶诺药业有限公司 | 一类蛋白受体激酶抑制剂的制备和应用 |
CN112979654A (zh) * | 2019-12-16 | 2021-06-18 | 成都倍特药业有限公司 | 杂芳基稠环化合物、其制备方法及应用 |
CN113861198A (zh) * | 2020-06-30 | 2021-12-31 | 上海医药集团股份有限公司 | 咪唑并[4,5-b]吡嗪类化合物、其制备方法及应用 |
WO2022095909A1 (zh) * | 2020-11-03 | 2022-05-12 | 上海瑶琪生物科技有限公司 | 用作ntrk激酶抑制剂的化合物及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107072985B (zh) | 治疗性抑制化合物 | |
JP5752232B2 (ja) | プロテインキナーゼ阻害剤としての置換ピロロトリアジン化合物 | |
ES2324837T3 (es) | Derivados de piridina utiles como inhibidores de la pkc-theta. | |
ES2907676T3 (es) | Inhibidores de la desmetilasa 1 específica de lisina | |
JP6600365B2 (ja) | Jak阻害剤 | |
BR112020000284A2 (pt) | amidas heterocíclicas de 5 membros e bicíclicas como inibidores de rock | |
JP2006503010A (ja) | 数種の新規なイミダゾピリジンおよびその使用 | |
WO2016112846A1 (zh) | 3-乙炔基吡唑并嘧啶衍生物及其制备方法和用途 | |
WO2021043322A1 (zh) | 氮杂环庚烷并嘧啶类衍生物及其医药用途 | |
AU2015276699B2 (en) | Pyridino[1,2-a]pyrimidone analogue used as PI3K inhibitor | |
BRPI0713328A2 (pt) | derivados de piridina e pirazina como inibidores de cinase mnk | |
WO2013170671A1 (zh) | 蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用 | |
CN114401955A (zh) | 细胞周期蛋白依赖性激酶的抑制剂 | |
JP2023504866A (ja) | 大環構造を有するフッ素含有複素環誘導体およびその用途 | |
WO2020233618A1 (zh) | 一类细胞程序性坏死抑制剂及其制备方法和用途 | |
US10654868B2 (en) | Dihydropyrazole azepine compound serving as Akt inhibitor | |
CN118176195A (zh) | 吡唑[3,4-d]嘧啶-3-酮类化合物及其医药用途 | |
CN115490671A (zh) | Parp7抑制剂及其制备方法 | |
CN115894381A (zh) | 一种2,4,5-三取代嘧啶类化合物及其制备方法和用途 | |
CN114989176A (zh) | 咪唑并哒嗪类衍生物及其应用 | |
CN115322158A (zh) | 作为krasg12c蛋白抑制剂的取代喹唑啉类化合物 | |
JP2024514015A (ja) | アルキニルフェニルベンズアミド化合物およびその使用 | |
CN111606888B (zh) | 吡咯类衍生物及其制备方法与应用 | |
CN115843296B (zh) | Cdk9抑制剂及其用途 | |
WO2024056091A1 (zh) | 作为rsk抑制剂的吡啶酮并嘧啶衍生物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |